Kiniksa Pharmaceuticals International (KNSA) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Mirum Pharmaceuticals (MIRM) over the past year, gaining 105.6% versus a gain of 11.7%. Over five years, KNSA leads with a +587.8% price change compared with +375.2% for MIRM. Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $5.28 billion), about 1.2 times the size.
Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -4.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | MIRM |
|---|---|---|
| Share price | $78.75 | $81.35 |
| Market cap | $6.14B | $5.28B |
| 1-day change | +1.01% | +0.88% |
| YTD return | +90.91% | +2.99% |
| 1-year return | +105.56% | +11.67% |
| 5-year return | +587.77% | +375.18% |
| P/E ratio (TTM) | 79.55 | — |
| Forward P/E | 48.69 | — |
| EPS (TTM) | $0.99 | $-14.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $521.31M |
| Revenue growth (YoY) | +60.09% | +54.74% |
| Net income (latest FY) | $59.01M | $-23.36M |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | -4.25% |
| Net margin | 8.71% | -4.48% |
| 52-week high | $82.94 | $130.00 |
| 52-week low | $35.20 | $63.23 |
| Distance from 52-week high | -5.05% | -37.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.44% | +79.21% |
| Average volume | 578.96K | 695.76K |
| Shares outstanding | 48.29M | 64.93M |
| Employees | 366 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed MIRM by 93.9 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -4.5 cents for Mirum Pharmaceuticals.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +54.74%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
KNSA vs MIRM FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Mirum Pharmaceuticals?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $5.28B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, KNSA or MIRM?
KNSA returned +105.56% over the past 12 months, compared with +11.67% for MIRM (price return, excluding dividends). Past performance does not predict future results.
Are Kiniksa Pharmaceuticals International and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.